150 related articles for article (PubMed ID: 37769252)
1. Efficacy and safety of anti-interleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis.
Kilic B; Guler Y; Azman FN; Bostanci E; Ugurlu S
Rheumatology (Oxford); 2024 Apr; 63(4):925-935. PubMed ID: 37769252
[TBL] [Abstract][Full Text] [Related]
2. Interventions for reducing inflammation in familial Mediterranean fever.
Yin X; Tian F; Wu B; Xu T
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD010893. PubMed ID: 35349164
[TBL] [Abstract][Full Text] [Related]
3. Interventions for reducing inflammation in familial Mediterranean fever.
Wu B; Xu T; Li Y; Yin X
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010893. PubMed ID: 30338514
[TBL] [Abstract][Full Text] [Related]
4. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
[TBL] [Abstract][Full Text] [Related]
5. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
[TBL] [Abstract][Full Text] [Related]
6. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
7. Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry.
Sag E; Akal F; Atalay E; Akca UK; Demir S; Demirel D; Batu ED; Bilginer Y; Ozen S
Rheumatology (Oxford); 2020 Nov; 59(11):3324-3329. PubMed ID: 32306038
[TBL] [Abstract][Full Text] [Related]
8. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
Karabulut Y; Gezer HH; Duruöz MT
Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
[TBL] [Abstract][Full Text] [Related]
9. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
Front Immunol; 2020; 11():971. PubMed ID: 32670263
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever.
Erkilet HK; Gezgin Yildirim D; Esmeray P; Söylemezoğlu O
Pediatr Int; 2023; 65(1):e15588. PubMed ID: 37658625
[TBL] [Abstract][Full Text] [Related]
12. The clinical role of anakinra in the armamentarium against familial Mediterranean fever.
Parlar K; Ates MB; Egeli BH; Ugurlu S
Expert Rev Clin Immunol; 2024 May; 20(5):441-453. PubMed ID: 38133629
[TBL] [Abstract][Full Text] [Related]
13. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.
Hashkes PJ; Spalding SJ; Giannini EH; Huang B; Johnson A; Park G; Barron KS; Weisman MH; Pashinian N; Reiff AO; Samuels J; Wright DA; Kastner DL; Lovell DJ
Ann Intern Med; 2012 Oct; 157(8):533-41. PubMed ID: 23070486
[TBL] [Abstract][Full Text] [Related]
14. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
Gül A
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S
J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
[TBL] [Abstract][Full Text] [Related]
16. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
[TBL] [Abstract][Full Text] [Related]
17. IL-1 inhibition in familial Mediterranean fever: clinical outcomes and expectations.
Kharouf F; Tsemach-Toren T; Ben-Chetrit E
Clin Exp Rheumatol; 2022 Sep; 40(8):1567-1574. PubMed ID: 36062765
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
[TBL] [Abstract][Full Text] [Related]
19. IL-1β biological treatment of familial Mediterranean fever.
Soriano A; Verecchia E; Afeltra A; Landolfi R; Manna R
Clin Rev Allergy Immunol; 2013 Aug; 45(1):117-30. PubMed ID: 23322405
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.
Atas N; Eroglu GA; Sodan HN; Ozturk BO; Babaoglu H; Satis H; Karadeniz H; Guler AA; Salman RB; Goker B; Ozturk MA; Haznedaroglu S; Tufan A
Clin Exp Rheumatol; 2021; 39 Suppl 132(5):30-36. PubMed ID: 34251317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]